Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lessened its stake in Editas Medicine, Inc. (NASDAQ:EDIT) by 10.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,639 shares of the company’s stock after selling 13,310 shares during the period. Los Angeles Capital Management LLC owned 0.14% of Editas Medicine worth $401,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. International Assets Investment Management LLC boosted its stake in Editas Medicine by 10.5% in the second quarter. International Assets Investment Management LLC now owns 31,457 shares of the company’s stock valued at $147,000 after acquiring an additional 3,000 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Editas Medicine by 10.1% in the second quarter. The Manufacturers Life Insurance Company now owns 33,599 shares of the company’s stock valued at $157,000 after acquiring an additional 3,089 shares in the last quarter. Rhumbline Advisers boosted its stake in Editas Medicine by 2.9% in the second quarter. Rhumbline Advisers now owns 137,986 shares of the company’s stock valued at $644,000 after acquiring an additional 3,862 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Editas Medicine by 20.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 24,485 shares of the company’s stock valued at $83,000 after acquiring an additional 4,089 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Editas Medicine by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 15,863 shares of the company’s stock valued at $54,000 after acquiring an additional 6,202 shares in the last quarter. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Trading Down 4.0 %

Shares of Editas Medicine stock opened at $2.66 on Monday. Editas Medicine, Inc. has a 12-month low of $2.59 and a 12-month high of $11.69. The stock has a market cap of $219.58 million, a PE ratio of -1.04 and a beta of 2.01. The company has a 50-day moving average of $3.33 and a two-hundred day moving average of $4.38.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Monday, November 4th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.75). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $3.93 million. During the same period last year, the company posted ($0.55) earnings per share. The firm’s quarterly revenue was down 98.9% compared to the same quarter last year. On average, sell-side analysts forecast that Editas Medicine, Inc. will post -2.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EDIT has been the subject of several research analyst reports. Barclays decreased their price objective on shares of Editas Medicine from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. Stifel Nicolaus decreased their target price on shares of Editas Medicine from $17.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 5th. Raymond James downgraded shares of Editas Medicine from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th. Bank of America upgraded shares of Editas Medicine from a “neutral” rating to a “buy” rating and increased their target price for the stock from $13.00 to $15.00 in a research note on Thursday, August 8th. Finally, Wells Fargo & Company decreased their target price on shares of Editas Medicine from $9.00 to $7.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.08.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.